Rab K. Prinjha

19.2k total citations · 3 hit papers
106 papers, 6.7k citations indexed

About

Rab K. Prinjha is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Rab K. Prinjha has authored 106 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 34 papers in Hematology and 20 papers in Immunology. Recurrent topics in Rab K. Prinjha's work include Protein Degradation and Inhibitors (60 papers), Multiple Myeloma Research and Treatments (28 papers) and Ubiquitin and proteasome pathways (25 papers). Rab K. Prinjha is often cited by papers focused on Protein Degradation and Inhibitors (60 papers), Multiple Myeloma Research and Treatments (28 papers) and Ubiquitin and proteasome pathways (25 papers). Rab K. Prinjha collaborates with scholars based in United Kingdom, United States and Germany. Rab K. Prinjha's co-authors include Alexander Tarakhovsky, David F. Tough, Chun‐wa Chung, Uwe Schaefer, Scott Dewell, Kevin Lee, Kate L. Jeffrey, Ivan Marazzi, Charles M. Rice and Rohit Chandwani and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Rab K. Prinjha

104 papers receiving 6.6k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Suppression of inflammation by a synthetic histone mimic

2010 1.2k citations Uwe Schaefer, Scott Dewell et al. profile →
Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways

2008 779 citations Rab K. Prinjha et al. profile →
Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription

2013 493 citations Minna U. Kaikkonen, Nathanael J. Spann et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rab K. Prinjha United Kingdom	40	4.9k	1.3k	1.3k	906	697	106	6.7k
Paolo Salomoni United Kingdom	45	4.8k 1.0×	1.1k 0.8×	852 0.7×	776 0.9×	1.4k 2.0×	104	6.5k
Silvano Capitani Italy	51	4.8k 1.0×	975 0.7×	1.6k 1.2×	711 0.8×	1.3k 1.8×	262	7.9k
Michaela Scherr Germany	36	3.3k 0.7×	585 0.4×	793 0.6×	1.1k 1.2×	654 0.9×	111	5.5k
JoAnn Trejo United States	50	3.9k 0.8×	1.8k 1.3×	758 0.6×	741 0.8×	558 0.8×	112	6.5k
Kathleen M. Sakamoto United States	41	6.2k 1.3×	1.3k 1.0×	983 0.8×	699 0.8×	2.3k 3.2×	188	8.2k
Roberto Testi Italy	47	4.2k 0.9×	375 0.3×	3.0k 2.3×	442 0.5×	795 1.1×	113	7.4k
Jun Qi United States	46	7.7k 1.6×	2.3k 1.7×	611 0.5×	698 0.8×	1.8k 2.6×	177	9.3k
Christian Seiser Austria	42	4.8k 1.0×	701 0.5×	569 0.4×	352 0.4×	836 1.2×	83	5.6k
Kris A. Reedquist Netherlands	43	2.9k 0.6×	585 0.4×	2.1k 1.6×	508 0.6×	1.1k 1.6×	91	5.6k
Burkhart Schraven Germany	49	3.2k 0.7×	478 0.4×	4.3k 3.3×	457 0.5×	1.3k 1.8×	200	7.7k

Countries citing papers authored by Rab K. Prinjha

Since Specialization

Citations

This map shows the geographic impact of Rab K. Prinjha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rab K. Prinjha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rab K. Prinjha more than expected).

Fields of papers citing papers by Rab K. Prinjha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rab K. Prinjha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rab K. Prinjha. The network helps show where Rab K. Prinjha may publish in the future.

Co-authorship network of co-authors of Rab K. Prinjha

This figure shows the co-authorship network connecting the top 25 collaborators of Rab K. Prinjha. A scholar is included among the top collaborators of Rab K. Prinjha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rab K. Prinjha. Rab K. Prinjha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Xiuquan, James Rickard, Catherine N. Hall, et al.. (2025). NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Science Advances. 11(28). eadv0079–eadv0079.

Sardini, Alessandro, Mathew Van de Pette, Andrew Dimond, et al.. (2023). Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition. Communications Biology. 6(1). 318–318. 3 indexed citations

Bradley, Erin K., Chun‐wa Chung, Peter D. Craggs, et al.. (2023). Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe. Journal of Medicinal Chemistry. 66(23). 15728–15749. 6 indexed citations

James, David W., Lavinia Margarit, Nagindra Das, et al.. (2023). In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British Journal of Cancer. 129(1). 163–174. 2 indexed citations

Ghiboub, Mohammed, Matthew Bell, Dovilė Sinkevičiūtė, et al.. (2023). The Epigenetic Reader Protein SP140 Regulates Dendritic Cell Activation, Maturation and Tolerogenic Potential. Current Issues in Molecular Biology. 45(5). 4228–4245. 1 indexed citations

Cuartero, Sergi, Adrià Cañellas‐Socias, Sarah Wells, et al.. (2022). Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters. Nature Communications. 13(1). 4342–4342. 20 indexed citations

Verhoeff, Jan, Andrew Y. F. Li Yim, V Joustra, et al.. (2022). A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease. Cells. 11(18). 2846–2846. 4 indexed citations

Kalxdorf, Mathias, William L. Thompson, H. Christian Eberl, et al.. (2021). IFN-γ Drives Human Monocyte Differentiation into Highly Proinflammatory Macrophages That Resemble a Phenotype Relevant to Psoriasis. The Journal of Immunology. 207(2). 555–568. 32 indexed citations

Brown, Jack A., Monica Simeoni, Peter Williams, et al.. (2021). A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor. British Journal of Clinical Pharmacology. 88(5). 2140–2155. 5 indexed citations

10.

Cribbs, Adam P., Martin Philpott, Jeroen Baardman, et al.. (2020). Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. Proceedings of the National Academy of Sciences. 117(11). 6056–6066. 73 indexed citations

11.

Tomkinson, Nicholas C. O., et al.. (2019). Advancements in the Development of non‐BET Bromodomain Chemical Probes. ChemMedChem. 14(4). 362–385. 37 indexed citations

12.

Bardini, Michela, Luca Trentin, Francesca Rizzo, et al.. (2018). Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics. 17(8). 1705–1716. 15 indexed citations

13.

Law, Robert P., Stephen J. Atkinson, Paul Bamborough, et al.. (2018). Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Journal of Medicinal Chemistry. 61(10). 4317–4334. 85 indexed citations

14.

Dobenecker, Marc‐Werner, Joon Seok Park, Michael T. McCabe, et al.. (2018). Signaling function of PRC2 is essential for TCR-driven T cell responses. The Journal of Experimental Medicine. 215(4). 1101–1113. 38 indexed citations

15.

Schilderink, Ronald, Matthew Bell, Inmaculada Rioja, et al.. (2016). BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. Molecular Immunology. 79. 66–76. 23 indexed citations

16.

Klein, Kerstin, Pawel A. Kabala, Aleksander M. Grabiec, et al.. (2014). The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases. 75(2). 422–429. 119 indexed citations

17.

Demont, Emmanuel H., Paul Bamborough, Chun‐wa Chung, et al.. (2014). 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Medicinal Chemistry Letters. 5(11). 1190–1195. 68 indexed citations

18.

Kaikkonen, Minna U., Nathanael J. Spann, Sven Heinz, et al.. (2013). Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription. Molecular Cell. 51(3). 310–325. 493 indexed citations breakdown →

19.

Fang, Terry, Uwe Schaefer, Ingrid Mecklenbräuker, et al.. (2012). Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. The Journal of Experimental Medicine. 209(4). 661–669. 132 indexed citations

20.

Vinson, Mary, Oliver Rausch, Peter R. Maycox, et al.. (2003). Lipid rafts mediate the interaction between myelin-associated glycoprotein (MAG) on myelin and MAG-receptors on neurons. Molecular and Cellular Neuroscience. 22(3). 344–352. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact